Departments of1Bioengineering.
2Pharmacology and Toxicology, and.
Neurosurg Focus. 2023 Jun;54(6):E4. doi: 10.3171/2023.3.FOCUS2379.
Gliomas exhibit high intratumor and interpatient heterogeneity. Recently, it has been shown that the microenvironment and phenotype differ significantly between the glioma core (inner) and edge (infiltrating) regions. This proof-of-concept study differentiates metabolic signatures associated with these regions, with the potential for prognosis and targeted therapy that could improve surgical outcomes.
Paired glioma core and infiltrating edge samples were obtained from 27 patients after craniotomy. Liquid-liquid metabolite extraction was performed on the samples and metabolomic data were obtained via 2D liquid chromatography-mass spectrometry/mass spectrometry. To gauge the potential of metabolomics to identify clinically relevant predictors of survival from tumor core versus edge tissues, a boosted generalized linear machine learning model was used to predict metabolomic profiles associated with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation.
A panel of 66 (of 168) metabolites was found to significantly differ between glioma core and edge regions (p ≤ 0.05). Top metabolites with significantly different relative abundances included DL-alanine, creatine, cystathionine, nicotinamide, and D-pantothenic acid. Significant metabolic pathways identified by quantitative enrichment analysis included glycerophospholipid metabolism; butanoate metabolism; cysteine and methionine metabolism; glycine, serine, alanine, and threonine metabolism; purine metabolism; nicotinate and nicotinamide metabolism; and pantothenate and coenzyme A biosynthesis. The machine learning model using 4 key metabolites each within core and edge tissue specimens predicted MGMT promoter methylation status, with AUROCEdge = 0.960 and AUROCCore = 0.941. Top metabolites associated with MGMT status in the core samples included hydroxyhexanoycarnitine, spermine, succinic anhydride, and pantothenic acid, and in the edge samples metabolites included 5-cytidine monophosphate, pantothenic acid, itaconic acid, and uridine.
Key metabolic differences are identified between core and edge tissue in glioma and, furthermore, demonstrate the potential for machine learning to provide insight into potential prognostic and therapeutic targets.
神经胶质瘤表现出高度的肿瘤内异质性和患者间异质性。最近,研究表明,胶质瘤的核心(内部)和边缘(浸润)区域之间的微环境和表型有显著差异。这项概念验证研究区分了与这些区域相关的代谢特征,有可能改善预后和靶向治疗,从而提高手术效果。
在开颅手术后,从 27 名患者中获得配对的胶质瘤核心和浸润边缘样本。对样本进行液-液代谢物提取,并通过二维液相色谱-质谱/质谱获得代谢组学数据。为了评估代谢组学在识别肿瘤核心与边缘组织中与生存相关的临床相关预测因子方面的潜力,使用增强型广义线性机器学习模型来预测与 O6-甲基鸟嘌呤 DNA 甲基转移酶(MGMT)启动子甲基化相关的代谢组学谱。
发现 66 种(168 种中的 66 种)代谢物在胶质瘤核心和边缘区域之间有显著差异(p≤0.05)。相对丰度有显著差异的顶级代谢物包括 DL-丙氨酸、肌酸、胱硫醚、烟酰胺和 D-泛酸。通过定量富集分析鉴定出显著的代谢途径包括甘油磷脂代谢;丁酸代谢;半胱氨酸和蛋氨酸代谢;甘氨酸、丝氨酸、丙氨酸和苏氨酸代谢;嘌呤代谢;烟酸和烟酰胺代谢;以及泛酸和辅酶 A 生物合成。使用每个核心和边缘组织标本中的 4 种关键代谢物的机器学习模型预测 MGMT 启动子甲基化状态,AUROCEdge=0.960,AUROCCore=0.941。与核心样本中 MGMT 状态相关的顶级代谢物包括羟基己酰肉碱、精胺、琥珀酸酐和泛酸,而在边缘样本中,代谢物包括 5-胞苷一磷酸、泛酸、异柠檬酸和尿苷。
在神经胶质瘤中,核心和边缘组织之间存在关键的代谢差异,此外,还表明机器学习有可能提供对潜在预后和治疗靶点的深入了解。